药物治疗高血压的现在和未来:概述
1INCLIVA Research Institute, University of Valencia, Valencia, Spain.
Blood pressure
|March 6, 2024
概括
由于高死亡率,高血压 (HBP) 管理至关重要. 新的抗高血压药物提供了更好的疗效,减少了副作用和器官保护,提高了患者的治疗结果.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 内部医学 内部医学
背景情况:
- 高血压 (HBP) 是导致死亡和残疾的主要原因,其患病率不断增加.
- 有效的HBP诊断和治疗对于预防并发症至关重要.
- 药物治疗仍然是高血压管理的基石.
研究的目的:
- 审查目前抗高血压药物类别的现状.
- 为了突出最近抗高血压疗法的进展.
- 讨论提供器官保护和改善合规性的新药.
主要方法:
- 审查当前的抗高血压药物类别及其机制.
- 对最近引入的抗高血压药物的分析.
- 探索新的注射途径和药物遗传学方法.
主要成果:
- 现有的药物向血压调节和高血压引起的器官损伤.
- 新的抗高血压药物提供了对器官损伤和代谢障碍的额外保护.
- 新兴策略包括针对特定适应症的药物,药物基因组学方法以及皮下注射等替代性注射途径.
结论:
- 概述了各种抗高血压药物类别的关键特征.
- 最近的进展侧重于提高疗效,减少不良影响和多方面的器官保护.
- 未来的方向包括个性化医疗和改进的药物输送系统,以更好地满足患者的要求.
相关概念视频
Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
Antihypertensive Drugs: Action of Diuretics
690
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
690
Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K


